Genmab — November 2016
-
Venter opkoebsboelge indenfor pharma/biotek http://www.dn.no/nyheter/2016/11/18/1814/helse/venter-oppkjopsbolge-etter-trump-seier
-
Syntes nu det er en meget naturlig stilling i et biotek selskab - "The main focus of the role will be to provide strategic input for all regulatory activities, such as filings as well as preparing and overseeing regulatory submissions to any international health authority – including management and oversight of timely delivery of documentation for research, nonclinical and clinical development.
" -
-
Det er der ingen logik i. Hvorfor solgte JNJ så Genmab aktier i starten af året. Ovenikøbet lige efter kursen var gået kraftigt ned.
-
Winkel sage til Bloomberg efter Jefferies, jf Børsen; at vi kan være opkøbsmål, men vi vil gerne være uafhængige. Han sagde til De Telegraff odæigere på året; at Genmab bliver mere og mere interessant for JNJ og blev det dem ville det være en venlig overtagelse....
-

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind